Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
BACKGROUNDSerum autoantibodies such as antinuclear antibody (ANA) are frequently detected in patients with chronic hepatitis C virus (HCV) infection, but its relevance is a matter of discussion. AIMTo assess the association of ANA positivity with clinical and histological features, and with the outc...
Gespeichert in:
| Veröffentlicht in: | European journal of gastroenterology & hepatology 2009-04, Vol.21 (4), p.350-356 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 356 |
|---|---|
| container_issue | 4 |
| container_start_page | 350 |
| container_title | European journal of gastroenterology & hepatology |
| container_volume | 21 |
| creator | Narciso-Schiavon, Janaína L Freire, Fernanda Caruso F Suarez, Marcelo Mendes Ferrari, Marcus Vinícius O Scanhola, Gustavo Quirino Schiavon, Leonardo de Lucca Carvalho Filho, Roberto J. de Ferraz, Maria Lucia G Silva, Antonio Eduardo B |
| description | BACKGROUNDSerum autoantibodies such as antinuclear antibody (ANA) are frequently detected in patients with chronic hepatitis C virus (HCV) infection, but its relevance is a matter of discussion.
AIMTo assess the association of ANA positivity with clinical and histological features, and with the outcome of antiviral therapy in patients with HCV infection.
METHODSBaseline samples from patients with hepatitis C treated with interferon and ribavirin were tested for ANA positivity by indirect immunofluorescence.
RESULTSThe mean age was 48.3±11.1 years and 56% were men. Among 234 included patients, 22 patients (9.4%) were positive for ANA. These patients showed significantly higher median alanine aminotransferase level (3.52 vs. 2.39 x upper limit of normal, P=0.009) when compared with ANA-negative patients. Fibrosis stage and necroinflammatory grading were not influenced by ANA positivity. Sustained virological response (SVR) rates were similar between ANA-positive and ANA-negative patients (27 vs. 29%, P=0.882). Alanine aminotransferase flares (≥1.5-fold the baseline) during treatment were observed in 28 patients (12%), irrespective of the presence of ANA and without any clinical significance.
CONCLUSIONAmong HCV patients, ANA positivity seems to represent an immunological epiphenomenon. It neither influences clinical, biochemical, and histological features of chronic hepatitis C nor predicts response to antiviral treatment. |
| doi_str_mv | 10.1097/MEG.0b013e3283089392 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733992858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733327317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3988-6db045a441dad7a641639bf28af8c5d1105a24e6bec3bd5b4d5e46f92b3dadec3</originalsourceid><addsrcrecordid>eNqNkU9v1DAQxS0EotvCN0DIF9RTyvhPEpsLqlalIBVxAYlb5DgTxeB1gu10td8er7pqJU4cRraffvPGmkfIGwZXDHT7_uvN7RX0wAQKrgQoLTR_RjZMtqKqG9U-JxvQtawazX6ekfOUfgGwVrD2JTljWigugG1IuA7ZhdV6NJGacu_n4UCXObns7l0-UBfoYrLDkBPduzxRO8U5OEsnPOrZJbr9QK13RTPeH2hEj_fFic5HQ4qLWyYM865U-PiKvBiNT_j6dF6QH59uvm8_V3ffbr9sr-8qK7RSVTP0IGsjJRvM0JpGskbofuTKjMrWA2NQGy6x6dGKfqh7OdQom1HzXpSGIl6QywffJc5_Vky527lk0XsTcF5T1wqhNVe1-h9S8OPaCikfSBvnlCKO3RLdzsRDx6A7RtKVSLp_Iyltb08D1n6Hw1PTKYMCvDsBJpUVjtEE69Ijx5moRdvA0_z97DPG9Nuve4zdhMbnqQMAWf7ZVhxAgyzPqhQo8ReoNaai</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733327317</pqid></control><display><type>article</type><title>Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Narciso-Schiavon, Janaína L ; Freire, Fernanda Caruso F ; Suarez, Marcelo Mendes ; Ferrari, Marcus Vinícius O ; Scanhola, Gustavo Quirino ; Schiavon, Leonardo de Lucca ; Carvalho Filho, Roberto J. de ; Ferraz, Maria Lucia G ; Silva, Antonio Eduardo B</creator><creatorcontrib>Narciso-Schiavon, Janaína L ; Freire, Fernanda Caruso F ; Suarez, Marcelo Mendes ; Ferrari, Marcus Vinícius O ; Scanhola, Gustavo Quirino ; Schiavon, Leonardo de Lucca ; Carvalho Filho, Roberto J. de ; Ferraz, Maria Lucia G ; Silva, Antonio Eduardo B</creatorcontrib><description>BACKGROUNDSerum autoantibodies such as antinuclear antibody (ANA) are frequently detected in patients with chronic hepatitis C virus (HCV) infection, but its relevance is a matter of discussion.
AIMTo assess the association of ANA positivity with clinical and histological features, and with the outcome of antiviral therapy in patients with HCV infection.
METHODSBaseline samples from patients with hepatitis C treated with interferon and ribavirin were tested for ANA positivity by indirect immunofluorescence.
RESULTSThe mean age was 48.3±11.1 years and 56% were men. Among 234 included patients, 22 patients (9.4%) were positive for ANA. These patients showed significantly higher median alanine aminotransferase level (3.52 vs. 2.39 x upper limit of normal, P=0.009) when compared with ANA-negative patients. Fibrosis stage and necroinflammatory grading were not influenced by ANA positivity. Sustained virological response (SVR) rates were similar between ANA-positive and ANA-negative patients (27 vs. 29%, P=0.882). Alanine aminotransferase flares (≥1.5-fold the baseline) during treatment were observed in 28 patients (12%), irrespective of the presence of ANA and without any clinical significance.
CONCLUSIONAmong HCV patients, ANA positivity seems to represent an immunological epiphenomenon. It neither influences clinical, biochemical, and histological features of chronic hepatitis C nor predicts response to antiviral treatment.</description><identifier>ISSN: 0954-691X</identifier><identifier>EISSN: 1473-5687</identifier><identifier>DOI: 10.1097/MEG.0b013e3283089392</identifier><identifier>PMID: 19382301</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Alanine Transaminase - blood ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies, Antinuclear - blood ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Biomarkers - blood ; Cross-Sectional Studies ; Drug Therapy, Combination ; Female ; Fluorescent Antibody Technique, Indirect - methods ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - immunology ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Ribavirin - therapeutic use ; Treatment Failure ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>European journal of gastroenterology & hepatology, 2009-04, Vol.21 (4), p.350-356</ispartof><rights>2009 Lippincott Williams & Wilkins, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3988-6db045a441dad7a641639bf28af8c5d1105a24e6bec3bd5b4d5e46f92b3dadec3</citedby><cites>FETCH-LOGICAL-c3988-6db045a441dad7a641639bf28af8c5d1105a24e6bec3bd5b4d5e46f92b3dadec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21353760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19382301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Narciso-Schiavon, Janaína L</creatorcontrib><creatorcontrib>Freire, Fernanda Caruso F</creatorcontrib><creatorcontrib>Suarez, Marcelo Mendes</creatorcontrib><creatorcontrib>Ferrari, Marcus Vinícius O</creatorcontrib><creatorcontrib>Scanhola, Gustavo Quirino</creatorcontrib><creatorcontrib>Schiavon, Leonardo de Lucca</creatorcontrib><creatorcontrib>Carvalho Filho, Roberto J. de</creatorcontrib><creatorcontrib>Ferraz, Maria Lucia G</creatorcontrib><creatorcontrib>Silva, Antonio Eduardo B</creatorcontrib><title>Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?</title><title>European journal of gastroenterology & hepatology</title><addtitle>Eur J Gastroenterol Hepatol</addtitle><description>BACKGROUNDSerum autoantibodies such as antinuclear antibody (ANA) are frequently detected in patients with chronic hepatitis C virus (HCV) infection, but its relevance is a matter of discussion.
AIMTo assess the association of ANA positivity with clinical and histological features, and with the outcome of antiviral therapy in patients with HCV infection.
METHODSBaseline samples from patients with hepatitis C treated with interferon and ribavirin were tested for ANA positivity by indirect immunofluorescence.
RESULTSThe mean age was 48.3±11.1 years and 56% were men. Among 234 included patients, 22 patients (9.4%) were positive for ANA. These patients showed significantly higher median alanine aminotransferase level (3.52 vs. 2.39 x upper limit of normal, P=0.009) when compared with ANA-negative patients. Fibrosis stage and necroinflammatory grading were not influenced by ANA positivity. Sustained virological response (SVR) rates were similar between ANA-positive and ANA-negative patients (27 vs. 29%, P=0.882). Alanine aminotransferase flares (≥1.5-fold the baseline) during treatment were observed in 28 patients (12%), irrespective of the presence of ANA and without any clinical significance.
CONCLUSIONAmong HCV patients, ANA positivity seems to represent an immunological epiphenomenon. It neither influences clinical, biochemical, and histological features of chronic hepatitis C nor predicts response to antiviral treatment.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cross-Sectional Studies</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fluorescent Antibody Technique, Indirect - methods</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Ribavirin - therapeutic use</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0954-691X</issn><issn>1473-5687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9v1DAQxS0EotvCN0DIF9RTyvhPEpsLqlalIBVxAYlb5DgTxeB1gu10td8er7pqJU4cRraffvPGmkfIGwZXDHT7_uvN7RX0wAQKrgQoLTR_RjZMtqKqG9U-JxvQtawazX6ekfOUfgGwVrD2JTljWigugG1IuA7ZhdV6NJGacu_n4UCXObns7l0-UBfoYrLDkBPduzxRO8U5OEsnPOrZJbr9QK13RTPeH2hEj_fFic5HQ4qLWyYM865U-PiKvBiNT_j6dF6QH59uvm8_V3ffbr9sr-8qK7RSVTP0IGsjJRvM0JpGskbofuTKjMrWA2NQGy6x6dGKfqh7OdQom1HzXpSGIl6QywffJc5_Vky527lk0XsTcF5T1wqhNVe1-h9S8OPaCikfSBvnlCKO3RLdzsRDx6A7RtKVSLp_Iyltb08D1n6Hw1PTKYMCvDsBJpUVjtEE69Ijx5moRdvA0_z97DPG9Nuve4zdhMbnqQMAWf7ZVhxAgyzPqhQo8ReoNaai</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Narciso-Schiavon, Janaína L</creator><creator>Freire, Fernanda Caruso F</creator><creator>Suarez, Marcelo Mendes</creator><creator>Ferrari, Marcus Vinícius O</creator><creator>Scanhola, Gustavo Quirino</creator><creator>Schiavon, Leonardo de Lucca</creator><creator>Carvalho Filho, Roberto J. de</creator><creator>Ferraz, Maria Lucia G</creator><creator>Silva, Antonio Eduardo B</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?</title><author>Narciso-Schiavon, Janaína L ; Freire, Fernanda Caruso F ; Suarez, Marcelo Mendes ; Ferrari, Marcus Vinícius O ; Scanhola, Gustavo Quirino ; Schiavon, Leonardo de Lucca ; Carvalho Filho, Roberto J. de ; Ferraz, Maria Lucia G ; Silva, Antonio Eduardo B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3988-6db045a441dad7a641639bf28af8c5d1105a24e6bec3bd5b4d5e46f92b3dadec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cross-Sectional Studies</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fluorescent Antibody Technique, Indirect - methods</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Ribavirin - therapeutic use</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Narciso-Schiavon, Janaína L</creatorcontrib><creatorcontrib>Freire, Fernanda Caruso F</creatorcontrib><creatorcontrib>Suarez, Marcelo Mendes</creatorcontrib><creatorcontrib>Ferrari, Marcus Vinícius O</creatorcontrib><creatorcontrib>Scanhola, Gustavo Quirino</creatorcontrib><creatorcontrib>Schiavon, Leonardo de Lucca</creatorcontrib><creatorcontrib>Carvalho Filho, Roberto J. de</creatorcontrib><creatorcontrib>Ferraz, Maria Lucia G</creatorcontrib><creatorcontrib>Silva, Antonio Eduardo B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Narciso-Schiavon, Janaína L</au><au>Freire, Fernanda Caruso F</au><au>Suarez, Marcelo Mendes</au><au>Ferrari, Marcus Vinícius O</au><au>Scanhola, Gustavo Quirino</au><au>Schiavon, Leonardo de Lucca</au><au>Carvalho Filho, Roberto J. de</au><au>Ferraz, Maria Lucia G</au><au>Silva, Antonio Eduardo B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?</atitle><jtitle>European journal of gastroenterology & hepatology</jtitle><addtitle>Eur J Gastroenterol Hepatol</addtitle><date>2009-04</date><risdate>2009</risdate><volume>21</volume><issue>4</issue><spage>350</spage><epage>356</epage><pages>350-356</pages><issn>0954-691X</issn><eissn>1473-5687</eissn><abstract>BACKGROUNDSerum autoantibodies such as antinuclear antibody (ANA) are frequently detected in patients with chronic hepatitis C virus (HCV) infection, but its relevance is a matter of discussion.
AIMTo assess the association of ANA positivity with clinical and histological features, and with the outcome of antiviral therapy in patients with HCV infection.
METHODSBaseline samples from patients with hepatitis C treated with interferon and ribavirin were tested for ANA positivity by indirect immunofluorescence.
RESULTSThe mean age was 48.3±11.1 years and 56% were men. Among 234 included patients, 22 patients (9.4%) were positive for ANA. These patients showed significantly higher median alanine aminotransferase level (3.52 vs. 2.39 x upper limit of normal, P=0.009) when compared with ANA-negative patients. Fibrosis stage and necroinflammatory grading were not influenced by ANA positivity. Sustained virological response (SVR) rates were similar between ANA-positive and ANA-negative patients (27 vs. 29%, P=0.882). Alanine aminotransferase flares (≥1.5-fold the baseline) during treatment were observed in 28 patients (12%), irrespective of the presence of ANA and without any clinical significance.
CONCLUSIONAmong HCV patients, ANA positivity seems to represent an immunological epiphenomenon. It neither influences clinical, biochemical, and histological features of chronic hepatitis C nor predicts response to antiviral treatment.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>19382301</pmid><doi>10.1097/MEG.0b013e3283089392</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-691X |
| ispartof | European journal of gastroenterology & hepatology, 2009-04, Vol.21 (4), p.350-356 |
| issn | 0954-691X 1473-5687 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733992858 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies, Antinuclear - blood Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Biomarkers - blood Cross-Sectional Studies Drug Therapy, Combination Female Fluorescent Antibody Technique, Indirect - methods Gastroenterology. Liver. Pancreas. Abdomen Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - immunology Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Ribavirin - therapeutic use Treatment Failure Treatment Outcome Viral diseases Viral hepatitis |
| title | Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A18%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antinuclear%20antibody%20positivity%20in%20patients%20with%20chronic%20hepatitis%20C:%20clinically%20relevant%20or%20an%20epiphenomenon?&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.au=Narciso-Schiavon,%20Jana%C3%ADna%20L&rft.date=2009-04&rft.volume=21&rft.issue=4&rft.spage=350&rft.epage=356&rft.pages=350-356&rft.issn=0954-691X&rft.eissn=1473-5687&rft_id=info:doi/10.1097/MEG.0b013e3283089392&rft_dat=%3Cproquest_cross%3E733327317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733327317&rft_id=info:pmid/19382301&rfr_iscdi=true |